You are here

Neumora Therapeutics

Neumora's dig into phase 3 depression data disappoints analysts

Fierce Biotech

Wed, 01/15/25 - 11:04 am

Neumora Therapeutics

clinical trials

5 Neuro Data Readouts to Watch in the Second Half of 2024

BioSpace

Mon, 07/15/24 - 11:43 am

clinical trials

Alzheimer's disease

Cerevel Therapeutics

Neumora Therapeutics

major depressive disorder

Wolfram syndrome

Vigil Neuroscience

Neumora's schizophrenia drug faces FDA hold over convulsions in rabbits

Fierce Biotech

Mon, 04/15/24 - 11:00 am

Neumora Therapeutics

clinical trials

After a record run, fewer biotechs are going public. Here’s how they’re performing.

BioPharma Dive

Tue, 12/19/23 - 11:42 am

Cargo Therapeutics

Lexeo Therapeutics

Neumora Therapeutics

Biopharma’s top 5 IPOs of 2023 (so far)

Pharma Voice

Thu, 11/30/23 - 10:01 am

Apogee Therapeutics

Neumora Therapeutics

Mineralys Therapeutics

How biotech IPOs performed in the third quarter

BioPharma Dive

Tue, 10/3/23 - 10:28 am

Neumora Therapeutics

Mira Pharmaceuticals

Turnstone Biologics

Apogee Therapeutics

Sagimet Biosciences

60 Degrees Pharma

5 Life Sciences IPOs in 2023—and the Future Forecast

BioSpace

Wed, 09/20/23 - 08:51 am

Neumora Therapeutics

Biotech Financing, IPO Tide May Be Turning – Signs of a Potential Recovery?

BioSpace

Sun, 09/17/23 - 09:45 pm

Neumora Therapeutics

Rome Therapeutics

Generate Biomedicines

RayzeBio, Neumora price some of biotech’s largest IPOs this year

BioPharma Dive

Thu, 09/14/23 - 11:02 pm

Neumora Therapeutics

Neumora, a richly funded brain drug developer, readies for an IPO

BioPharma Dive

Sun, 08/27/23 - 04:27 pm

Neumora Therapeutics

Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs

MedCity News

Thu, 10/7/21 - 12:19 pm

Neumora Therapeutics

drug development